Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05853575 · ClinicalTrials.gov registry record · Phase 2
Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)
A Phase 2 study of Advanced Cancer and Metastatic Cancer, sponsored by Mirati Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 200
- Enrollment target
- 20
- Study locations
NCT05853575 is a Phase 2 study of Advanced Cancer and Metastatic Cancer that is actively recruiting participants, run by Mirati Therapeutics. The registered enrollment target is 200 participants, below the 245-participant average among 122 other Advanced Cancer trials with a reported enrollment target (18% lower). The trial reports 20 study locations across 19 states.
The verdict
NCT05853575, a Phase 2 study of Advanced Cancer and Metastatic Cancer, is actively recruiting participants, sponsored by Mirati Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 200 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will evaluate the efficacy of two dosing regimens of adagrasib (600 mg BID versus 400 mg BID) in patients with NSCLC with KRAS G12C mutation.
Conditions Studied
Interventions
- DRUG Adagrasib
Study Locations (20)
Other
- A.C. Camargo Cancer Center - São Paulo
- A.C. Camargo Cancer Center - São Paulo
California
- Local Institution - 101 - Santa Rosa
Illinois
- Local Institution - 104 - Chicago
Minnesota
- Local Institution - 103 - Minneapolis
Missouri
- Kansas City VA Hospital - Kansas City
North Carolina
- Veterans Affairs Medical Center (VAMC) - Durham - Oncology - Durham
Texas
- VA North Texas Healthcare System/Dallas VA Medical Center - Dallas
Estado de Bahia
- Ensino e Terapia de Inovação Clinica AMO-ÉTICA / Ética Pesquisa e Ensino - Salvador
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2024-02-16 |
| Est. Completion | 2026-07-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05853575
The ClinicalTrials.gov registry entry for NCT05853575 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 245-participant average among 122 other Advanced Cancer trials with a reported enrollment target (18% lower). The listed sponsor is Mirati Therapeutics, which has 49 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Advanced Cancer appearing as the primary indexed condition, and to 1 intervention - of which Adagrasib is the first listed.
NCT05853575 reports 20 study locations spanning 19 distinct geographic areas - top geographies include Other, California, Illinois.
Frequently Asked Questions
What is clinical trial NCT05853575 about?
NCT05853575 is a clinical study titled "Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)". This study will evaluate the efficacy of two dosing regimens of adagrasib (600 mg BID versus 400 mg BID) in patients with NSCLC with KRAS G12C mutation.
What is the current status of trial NCT05853575?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 2024-02-16. Estimated completion is 2026-07-30.
What conditions does trial NCT05853575 study?
This clinical trial studies the following conditions: Advanced Cancer, Metastatic Cancer, Malignant Neoplasm of Lung.
What interventions are being tested in trial NCT05853575?
The interventions under investigation include: Adagrasib (DRUG).
Who is sponsoring clinical trial NCT05853575?
This trial is sponsored by Mirati Therapeutics, which has 49 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05853575 being conducted?
This trial has 20 study locations across California, Illinois, Minnesota, Missouri, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
RECRUITING · Phase 2
-
Psilocybin in Cancer Pain Study
RECRUITING · Phase 2
-
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
RECRUITING · Phase 2
-
Psilocybin Therapy in Advanced Cancer
RECRUITING · Phase 2
-
Psilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance Therapy
RECRUITING · Phase 2
-
Intrapleural Catheter Daily Versus Three Times a Week Drainage
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.